Posted by Michael Wonder on 21 Jul 2020
Molecular Partners provides regulatory update of European and Japanese filings of abicipar pegol
20 July 2020 - Molecular Partners today announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the EMA and the Japanese Regulatory Agency for abicipar pegol, a novel DARPin therapeutic for patients with neovascular (wet) age-related macular degeneration.
Following the recent decision from the U.S. FDA, AbbVie is committed to working with the regulatory agencies to determine the appropriate next steps and discuss requirements for potential resubmissions for abicipar pegol.
The company continues to believe in the need for new treatment options for neovascular age-related macular degeneration.
